REVIEW article
Front. Chem.
Sec. Medicinal and Pharmaceutical Chemistry
Volume 13 - 2025 | doi: 10.3389/fchem.2025.1642190
This article is part of the Research TopicRecent Advances in the Design of Heterocyclic Modulators of Druggable EnzymesView all articles
Comprehensive Medicinal Chemistry Survey Highlights A Portfolio of Lead Molecules for Alzheimer's Disease Therapy
Provisionally accepted
Pravin R Bhansali1*
Brian Muntean2*
Shashank M Sonkusare3
Shubhangi S Savale3
Yasanandana S. Wijayasinghe4Douglas C Sloan2Ganesh U Chaturbhuj3*- 1Alliance University, Bangalore, India
- 2Augusta University, Augusta, United States
- 3Institute of Chemical Technology, Mumbai, India
- 4Indiana University School of Medicine, Indianapolis, United States
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
The World Health Organization reports 10 million new patients with dementia each year. The most common form of dementia is Alzheimer's disease (AD), which constitutes up to 70% of cases. AD is mainly characterized by loss of memory, which, in addition to its debilitating individual effect, represents a burden of 1.3 trillion US dollars globally. The staggering scale of hardship has spurred intense investigations from the scientific community in search of therapeutic solutions. Recent advances to combat AD involve the identification of numerous neural targets and concomitant chemical interventions as nodes of therapy. Due to disparate biological and chemical facets of AD therapy, a comprehensive perspective covering both arenas is currently missing from the literature. This perspective aims to provide an extensive understanding of anti-AD mechanics alongside small-molecule drug design efforts from a medicinal chemist viewpoint. We are confident that this survey of the literature will provide a resourceful motivation to propel future research efforts towards successful Alzheimer's disease therapy.
Keywords: Alzheimer's disease, Dementia treatment, drug design, Medicinal Chemistry, Neurobiology of disease
Received: 06 Jun 2025; Accepted: 30 Jul 2025.
Copyright: © 2025 Bhansali, Muntean, Sonkusare, Savale, Wijayasinghe, Sloan and Chaturbhuj. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Pravin R Bhansali, Alliance University, Bangalore, India
Brian Muntean, Augusta University, Augusta, United States
Ganesh U Chaturbhuj, Institute of Chemical Technology, Mumbai, India
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.